Skip to main
GRI
GRI logo

GRI Stock Forecast & Price Target

GRI Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

GRI Bio Inc. presents an attractive investment opportunity based on its positive interim clinical data, indicating efficacy in treating serious immune-related disorders, particularly in the areas of fibrogenesis and lung function. The company's lead programs, GRI-0621 and GRI-0803, are uniquely positioned in the biotech space to address significant unmet medical needs, which enhances the potential for strong future revenue streams. Additionally, despite adjustments in price targets, the underlying net present value (NPV) analysis reflects substantial upside potential from the current stock price, making GRI Bio's valuation compelling in light of the associated risks and rewards.

Bears say

GRI Bio Inc has reported a significant net loss of $3.4 million (EPS of $(1.28)) and $3.9 million (EPS of $(7.72)), which exceeded both its internal estimates and consensus expectations, indicating persistent financial underperformance. The company faces multiple risks, including liquidity and balance sheet concerns, the potential failure of its product candidates in clinical trials, and uncertain regulatory approvals, all of which could hinder its growth and commercialization efforts. Additionally, a complex competitive landscape and varying investor sentiment towards biotech stocks further contribute to a negative outlook on GRI Bio's financial sustainability and stock performance.

GRI has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About GRI Bio Inc (GRI) Forecast

Analysts have given GRI a Strong Buy based on their latest research and market trends.

According to 2 analysts, GRI has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

GRI Bio Inc (GRI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.